Flush with cash from their GLP-1 franchises, Eli Lilly and Novo Holdings have become the most active participants in Series A biotech funding. They are leveraging their deep pockets to stimulate company formation and strategically branch into new therapeutic areas, shaping the next wave of innovation.

After years of focusing on de-risked late-stage products, the M&A market is showing a renewed appetite for risk. Recent large deals for early-stage and platform companies signal a return to an era where buyers gamble on foundational science.

While hype cycles focus on novel areas, significant value exists in established markets like hypertension. By targeting refractory patient populations with high unmet needs (e.g., the 20% of hypertension patients not properly treated), biotechs can create valuable assets with novel mechanisms in fields that appear saturated.

Eli Lilly's market dominance stems from its 2018 bet on obesity drugs, a field then considered a 'non-market.' Their philosophy is that by the time a medical market is large and obvious, it's too late to invest in R&D. They prioritize investing where the science is profound, not where the market currently is.

As large pharmaceutical companies shift focus to acquiring clinically validated assets, a gap has emerged in early-stage development. Smaller and mid-sized pharmas, unable to compete on price for late-stage assets, are now incentivized to take on more risk and partner earlier, driving innovation.

After major pharma abandoned osteoporosis R&D due to costly trial failures, the field is experiencing a renaissance. The FDA's SABER initiative approved bone mineral density as a surrogate endpoint for registrational trials, slashing clinical trial sizes (e.g., from 15k to 1.5k patients), timelines, and costs, de-risking the space for new investment.

Skeletalis's platform targets osteoporosis with precision using "site-specific pharmacology." A small molecule anchors an inactive prodrug to the bone, where it is activated only by the cells causing bone loss. This localized approach dramatically improves the safety profile and therapeutic index, enabling the use of novel biological targets that would be too risky for systemic delivery.

A profound capital shift has occurred where both venture investors and large pharma partners focus on clinically validated assets. This moves investment away from riskier, early-stage science, creating a significant funding gap for foundational research and pre-clinical startups.

With 20 deals this year and only one in obesity, Eli Lilly is not just reinvesting in its core strength. It is leveraging massive cash flow to aggressively acquire early-stage (Phase 2 or earlier) and preclinical assets in new areas, a long-term luxury its competitors, who are constrained by near-term patent cliffs, cannot match.